InvivoGen's product citations
InvivoGen’s products are frequently cited in peer-reviewed publications for a wide variety of applications and uses. Browse our product citations below.
Please note: By clicking on the product name, you can access via the ‘Citations’ tab all references of the product (click ‘load more’).
Citations search
You can search by ‘Product Name’ or ‘Year’.
Product | Citation | Year | Journal | Authors | Page |
---|---|---|---|---|---|
Alhydrogel® adjuvant 2% | Spherical nucleic acids as an infectious disease vaccine platform. | 2022 | PNAS | Teplensky M.H. et al. | DOI: 10.1073/pnas.2119093119 |
Recombinant anti-mouse IL-13 antibody | Interferon gamma constrains type 2 lymphocyte niche boundaries during mixed i... | 2022 | Immunity | Cautivo K.M. et al. | DOI: 10.1016/j.immuni.2021.12.014 |
Recombinant anti-mouse IL-13 antibody | The Presence of Interleukin-13 at Pancreatic ADM/PanIN Lesions Alters Macroph... | 2017 | Cell Rep. | Liou G.Y. et al. | DOI: 10.1016/j.celrep.2017.04.052 |
Anti-hIL-17a | Mucosal-associated invariant T cells are associated with insulin resistance i... | 2022 | Diabetologia | Berg R. et al. | DOI: 10.1007/s00125-022-05682-w |
NLRP3 inflammasome inhibitor - MCC950 | Motoneuronal inflammasome activation triggers excessive neuroinflammation and... | 2022 | J Neuroinflammation | Molnár K. et al. | DOI: 10.1186/s12974-022-02427-9 |
Normocin® - Antimicrobial Reagent | Determining the effects of loss of function mutations in human cell lines. | 2022 | STAR Protoc. | de Prisco N. et al. | DOI: 10.1016/j.xpro.2022.101232 |
2'3'-cGAMP | Human rhinovirus promotes STING trafficking to replication organelles to prom... | 2022 | Nat Commun | Triantafilou M. et al. | DOI: 10.1038/s41467-022-28745-3 |
RU.521 | Human rhinovirus promotes STING trafficking to replication organelles to prom... | 2022 | Nat Commun | Triantafilou M. et al. | DOI: 10.1038/s41467-022-28745-3 |
pUNO-mcs control plasmids | Human rhinovirus promotes STING trafficking to replication organelles to prom... | 2022 | Nat Commun | Triantafilou M. et al. | DOI: 10.1038/s41467-022-28745-3 |
BX795 | Human rhinovirus promotes STING trafficking to replication organelles to prom... | 2022 | Nat Commun | Triantafilou M. et al. | DOI: 10.1038/s41467-022-28745-3 |
LyoVec™ | Human rhinovirus promotes STING trafficking to replication organelles to prom... | 2022 | Nat Commun | Triantafilou M. et al. | DOI: 10.1038/s41467-022-28745-3 |
Anti-Flagellin | Salmonella Typhimurium O-antigen and VisP play an important role in swarming ... | 2022 | Braz J Microbiol. | Manieri F.Z. & Moreira C.G. | DOI: 10.1007/s42770-022-00701-9 |
HKSA | BTK inhibition limits B-cell-T-cell interaction through modulation of B-cell ... | 2022 | Acta Neuropathol | Li R. et al. | DOI: 10.1007/s00401-022-02411-w |
ODN 2006 (ODN 7909) | BTK inhibition limits B-cell-T-cell interaction through modulation of B-cell ... | 2022 | Acta Neuropathol | Li R. et al. | DOI: 10.1007/s00401-022-02411-w |
Human TLR5 Reporter HEK293 Cells (NF-κB) | Modulation of outer membrane vesicle-based immune responses by cathelicidins. | 2022 | Vaccine | Balhuizen M.D. et al. | DOI: 10.1016/j.vaccine.2022.03.015 |
Human TLR2 Reporter HEK293 Cells (NF-κB) | Modulation of outer membrane vesicle-based immune responses by cathelicidins. | 2022 | Vaccine | Balhuizen M.D. et al. | DOI: 10.1016/j.vaccine.2022.03.015 |
Human TLR3 Reporter HEK293 Cells (NF-κB) | Modulation of outer membrane vesicle-based immune responses by cathelicidins. | 2022 | Vaccine | Balhuizen M.D. et al. | DOI: 10.1016/j.vaccine.2022.03.015 |
HEK-Blue™ Null1 Cells | Modulation of outer membrane vesicle-based immune responses by cathelicidins. | 2022 | Vaccine | Balhuizen M.D. et al. | DOI: 10.1016/j.vaccine.2022.03.015 |
Blasticidin | Modulation of outer membrane vesicle-based immune responses by cathelicidins. | 2022 | Vaccine | Balhuizen M.D. et al. | DOI: 10.1016/j.vaccine.2022.03.015 |
Human TLR9 Reporter HEK293 Cells (NF-κB) | Modulation of outer membrane vesicle-based immune responses by cathelicidins. | 2022 | Vaccine | Balhuizen M.D. et al. | DOI: 10.1016/j.vaccine.2022.03.015 |